Abstract: The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor is characterized by abnormal vascular permeability. Diseases or disorders treated or prevented by administration of a composition including a therapeutically effective amount of a PKC zeta inhibitor include cancer, an ischemic condition and microvascular complications of a systemic or local condition in the subject, such as diabetes and/or diabetic macular edema. Additionally, methods of inhibiting PKC zeta are provided which include incubating PKC zeta in vivo, in vitro and/or in silico with a PKC zeta inhibitor.

Abstract: Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor is characterized by abnormal vascular permeability. Diseases or disorders treated or prevented by administration of a composition including a therapeutically effective amount of a PKC zeta inhibitor include cancer, an ischemic condition and microvascular complications of a systemic or local condition in the subject, such as diabetes and/or diabetic macular edema. Additionally, methods of inhibiting PKC zeta are provided which include incubating PKC zeta in vivo, in vitro and/or in silico with a PKC zeta inhibitor.

Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor is characterized by abnormal vascular permeability. Diseases or disorders treated or prevented by administration of a composition including a therapeutically effective amount of a PKC zeta inhibitor include cancer, an ischemic condition and microvascular complications of a systemic or local condition in the subject, such as diabetes and/or diabetic macular edema. Additionally, methods of inhibiting PKC zeta are provided which include incubating PKC zeta in vivo, in vitro and/or in silico with a PKC zeta inhibitor.

Abstract: The invention relates to compositions and methods for inhibiting sphingosine kinase and for treating hyperproliferative disease.

Abstract: The present invention provides 1H-quinoxalinones, of the formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, and n are as defined herein. Also disclosed are pharmaceutical compositions comprising such compounds, and methods for using the compounds to increase the therapeutic efficacy of drugs.

Abstract: The invention relates to compounds, compositions and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy.

Abstract: The present invention provides 2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamines, of the formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R7 are as defined herein. Also disclosed are pharmaceutical compositions comprising such compounds, and methods for using the compounds to increase the therapeutic efficacy of drugs.

Abstract: The invention is a pharmaceutical composition mainly for the treatment of a hyperproliferative disease, such as cancer, atherosclerosis, restenosis or psoriasis, or viral infection. The active ingredient of the composition is a compound that inhibits the activity of human N-myristoyltransferase (NMT). The NMT inhibitors are small molecule non-lipid compounds containing a cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine (COPP) or methyl-octahydro-pyrrolo[1,2-a]pyrazine (MOPP) group.

Abstract: The present invention provides chemical compounds, pharmaceutical compositions, and methods for increasing the therapeutic efficacy of drugs. Specifically, the invention provides compounds and compositions for inhibiting drug transport proteins that efflux therapeutic agents from cells, and to methods for using these compounds and pharmaceutical compositions to increase the efficacy of the therapeutic agents that are effluxed by these drug transport proteins.

Abstract: Byte-swapping in a buffer memory system utilizes a byte-swapping register to avoid wasteful unused buffer memory spaces that may result from a data transfer of partial word data, i.e., bytes of data less than the number of bytes in a word, to the buffer memory. When a data transfer request, e.g., a write request, requires a transfer of a partial word, the partial request is written to a word in the buffer memory, and is also stored in the byte-swapping register. In a subsequent data transfer request, the partial word stored in the byte-swapping register is combined and concatenated with sufficient bytes of data of the subsequent data transfer request to produce a complete word. The complete word is written in the word in the buffer memory, replacing the previously stored partial word, and thus fills the previously unused buffer memory space.

Abstract: The present invention provides 2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamines, of the formula: 1

Abstract: The present invention provides 1H-quinoxalinones, of the formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and n are as defined herein. Also disclosed are pharmaceutical compositions comprising such compounds, and methods for using the compounds to increase the therapeutic efficacy of drugs.

Abstract: The invention is an adjustable audible tempo device included in the handle of a golf club or within a clip-on tube attached to the golfer or a golf bag, which may be adjusted to a repetitive rhythmic audible meter, for the development of a consistent swing speed in the swinging of a golf club or a putter.

Abstract: The invention is an adjustable audible tempo device included in the handle of a golf club or within a clip-on tube attached to the golfer or a golf bag, which may be adjusted to a repetitive rhythmic audible meter, for the development of a consistent swing speed in the swinging of a golf club or a putter.

Abstract: The present invention provides chemical compounds, pharmaceutical compositions, and methods for increasing the therapeutic efficacy of drugs. Specifically, the invention provides compounds and compositions for inhibiting drug transport proteins that efflux therapeutic agents from cells, and to methods for using these compounds and pharmaceutical compositions to increase the efficacy of the therapeutic agents that are effluxed by these drug transport proteins.

Abstract: A remotely-controlled crib toy generates audio and/or video sensible output in response to user commands received by a remote control system. The nature and duration of the sensible output can be selected by the user. The sensible output is selected to be soothing to an infant.

Abstract: A cryptophycin compound is provided having the structure: ##STR1## Further provided are methods for producing novel cryptophycins from the Nostoc sp. of blue-green algae (cyanobacteria). Pharmaceutical compositions comprising novel cryptophycins are also provided, as are methods for using cryptophycins to inhibit the proliferation of hyperproliferative cells. Further provided are methods for using cryptophycins to inhibit the proliferation of hyperproliferative cells with drug resistant phenotypes, and to treat pathological conditions, such as neoplasia.